Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Debut Biotechnology Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 5 distinct examiners and 4 distinct art units. The examiner count exceeds the art-unit count, indicating that at least one art unit contains matters handled by more than one examiner.
CHI, AMANDA LYNN is the busiest examiner, with 1 pending matter. No examiner accounts for a larger share of the workload in the available data, so prosecution management should emphasize application-specific deadlines and issues.
The distribution across multiple examiners and units may require separate response strategies, particularly where the applications present different technical records. The profile does not establish whether the matters share claim language or prior-art issues.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHI, AMANDA LYNN | 1 | — | — |
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.3% |
| STEADMAN, DAVID J | 1 | 57.7% | +29.7% |
| PAK, YONG D | 1 | 74.7% | +14.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17720006 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | STEADMAN, DAVID J | 29d |
| 18804859 | FORMULATIONS OF DIHYDROKAEMPFEROL | CHI, AMANDA LYNN | — |
| 17720036 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | BREEN, KIMBERLY CATHERINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17720006 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | STEADMAN, DAVID J | 29d |
| 17720036 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | BREEN, KIMBERLY CATHERINE | — |
| 17720020 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | PAK, YONG D | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1657 | 1 |
| 1656 | 1 |
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18804859 | FORMULATIONS OF DIHYDROKAEMPFEROL | CHI, AMANDA LYNN | 1613 | §102§103§112 | Non-Final OA | — | Pending | Aug 14, 2024 |
| 17720036 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | BREEN, KIMBERLY CATHERINE | 1657 | §103 | Non-Final OA | — | Pending | Apr 13, 2022 |
| 17720006 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | STEADMAN, DAVID J | 1656 | §103§112Other | Final Rejection | 29d | Pending | Apr 13, 2022 |
| 17720020 | FLAVONOID AND ANTHOCYANIN BIOPRODUCTION USING MICROORGANISM HOSTS | PAK, YONG D | 1652 | §103 | Non-Final OA | — | Pending | Apr 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDebut Biotechnology Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Amanda Lynn Chi has the most, with 1 of Debut Biotechnology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
